Detalhe da pesquisa
1.
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Br J Haematol
; 185(3): 450-467, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30729512
2.
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 15(8): 874-85, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24948586
3.
Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study.
Bone Marrow Transplant
; 57(10): 1507-1513, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35768571
4.
Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial.
Bone Marrow Transplant
; 59(3): 431-434, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38195983
5.
Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma.
J Clin Oncol
; 37(19): 1617-1628, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30969846
6.
Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) Trial.
Br J Haematol
; 163(4): 541-3, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24033132
7.
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.
Cancer Res
; 66(12): 6379-86, 2006 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16778216
8.
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Lancet Haematol
; 3(7): e340-51, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27374467
9.
Novel uses for recombinant erythropoietin therapy in unlicensed indications.
Hematol J
; 5(2): 181-5, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15048070
10.
Adiponectin is produced by lymphocytes and is a negative regulator of granulopoiesis.
J Leukoc Biol
; 88(4): 807-11, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20643815
11.
Thalidomide-induced phrenic nerve paralysis.
Leuk Lymphoma
; 51(2): 342-4, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20038224
12.
The endogenous granulocyte colony-stimulating factor response following autologous peripheral blood stem cell transplantation is impaired in patients with myeloma.
Br J Haematol
; 117(3): 646-9, 2002 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12028037
13.
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Lancet Oncol
; 7(11): 958-9, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17081923
14.
Bone marrow architecture in acute myeloid/erythroid leukaemia.
Br J Haematol
; 126(1): 1, 2004 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-15198725